Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

Fig. 2

(A) Pro-apoptotic effects of DOX in combination with OKI-005. Representative plots of Annexin V/ PI in the cell lines CAL-51 (wild-type p53), MDA-MB-231 (mutant p53), Hs 578T (mutant p53), and CAL-120 (mutant p53) cell lines after 48 h of treatment with DOX (0.5 µM), OKI-005 (0.2 µM), or combination as measured by flow cytometry. (B) Statistical analysis of apoptosis via total Annexin V. Ordinary one-way ANOVA with Tukey correction comparing single agent to combination (* = p < 0.05, ** = P < 0.01; *** = P < 0.001). A trend (p = 0.058) for CAL-120 OKI-005 compared with the combination was observed. (C) Cell cycle analysis of DOX and OKI-005 for 24 h measured by flow cytometry via PI

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us